Eu Jeong Ku1, Dong-Hwa Lee1, Hyun Jeong Jeon1, Tae Keun Oh2. 1. Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea; Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Republic of Korea. 2. Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea; Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Republic of Korea. Electronic address: tgohkjs@chungbuk.ac.kr.
Abstract
AIMS: To directly compare the effectiveness and safety between two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, as part of a quadruple oral antidiabetic agents (OADs) in patients with inadequately controlled type 2 diabetes (T2D). METHODS: This study was an open-labeled, prospective, 52-week study conducted in T2D patients with glycated hemoglobin (HbA1c) ranging 7.5-12.0% with metformin, glimepiride and dipeptidyl peptidase-4 inhibitors. Patients were divided into either empagliflozin (25 mg/day) or dapagliflozin (10 mg/day). The outcome measures included changes in HbA1c, fasting plasma glucose (FPG), and cardiometabolic variables and the safety profiles. RESULTS: In total, 350 patients were enrolled with empagliflozin (n = 176) and dapagliflozin (n = 174), respectively. After 52 weeks, both groups showed significant reductions in HbA1c and FPG, but the reduction was greater in the empagliflozin group (P < 0.001). Both groups showed significantly decreased blood pressure and body weight and high-density lipoprotein cholesterol levels were increased in the empagliflozin (between groups, P = 0.035). Both groups showed similar safety profiles. CONCLUSIONS: Our study demonstrated that SGLT2 inhibitors can be effectively used as a fourth OAD in T2D patients who are treated with three other OADs. More specifically, empagliflozin was more effective in reducing HbA1c and improving other cardiometabolic parameters than dapagliflozin. Clinical Trial Number NCT03748810 (ClinicalTrials.gov).
AIMS: To directly compare the effectiveness and safety between two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, as part of a quadruple oral antidiabetic agents (OADs) in patients with inadequately controlled type 2 diabetes (T2D). METHODS: This study was an open-labeled, prospective, 52-week study conducted in T2D patients with glycated hemoglobin (HbA1c) ranging 7.5-12.0% with metformin, glimepiride and dipeptidyl peptidase-4 inhibitors. Patients were divided into either empagliflozin (25 mg/day) or dapagliflozin (10 mg/day). The outcome measures included changes in HbA1c, fasting plasma glucose (FPG), and cardiometabolic variables and the safety profiles. RESULTS: In total, 350 patients were enrolled with empagliflozin (n = 176) and dapagliflozin (n = 174), respectively. After 52 weeks, both groups showed significant reductions in HbA1c and FPG, but the reduction was greater in the empagliflozin group (P < 0.001). Both groups showed significantly decreased blood pressure and body weight and high-density lipoprotein cholesterol levels were increased in the empagliflozin (between groups, P = 0.035). Both groups showed similar safety profiles. CONCLUSIONS: Our study demonstrated that SGLT2 inhibitors can be effectively used as a fourth OAD in T2D patients who are treated with three other OADs. More specifically, empagliflozin was more effective in reducing HbA1c and improving other cardiometabolic parameters than dapagliflozin. Clinical Trial Number NCT03748810 (ClinicalTrials.gov).
Authors: Aimen Shafiq; Eman Mahboob; Muhammad Ammar Samad; Mohammad Hassam Ur Rehman; Zoaib Habib Tharwani Journal: Ann Med Surg (Lond) Date: 2022-09-02
Authors: Marcello Casaccia Bertoluci; João Eduardo Nunes Salles; José Silva-Nunes; Hermelinda Cordeiro Pedrosa; Rodrigo Oliveira Moreira; Rui Manuel Calado da Silva Duarte; Davide Mauricio da Costa Carvalho; Fábio Rogério Trujilho; João Filipe Cancela Dos Santos Raposo; Erika Bezerra Parente; Fernando Valente; Fábio Ferreira de Moura; Alexandre Hohl; Miguel Melo; Francisco Garcia Pestana Araujo; Rosa Maria Monteiro Castro de Araújo Principe; Rosane Kupfer; Adriana Costa E Forti; Cynthia Melissa Valerio; Hélder José Ferreira; João Manuel Sequeira Duarte; José Francisco Kerr Saraiva; Melanie Rodacki; Maria Helane Costa Gurgel Castelo; Mariana Pereira Monteiro; Patrícia Quadros Branco; Pedro Manuel Patricio de Matos; Pedro Carneiro de Melo Pereira de Magalhães; Roberto Tadeu Barcellos Betti; Rosângela Roginski Réa; Thaisa Dourado Guedes Trujilho; Lana Catani Ferreira Pinto; Cristiane Bauermann Leitão Journal: Diabetol Metab Syndr Date: 2020-05-24 Impact factor: 3.320
Authors: Jun Sung Moon; Sunghwan Suh; Sang Soo Kim; Heung Yong Jin; Jeong Mi Kim; Min Hee Jang; Kyung Ae Lee; Ju Hyung Lee; Seung Min Chung; Young Sang Lyu; Jin Hwa Kim; Sang Yong Kim; Jung Eun Jang; Tae Nyun Kim; Sung Woo Kim; Eonju Jeon; Nan Hee Cho; Mi-Kyung Kim; Hye Soon Kim; Il Seong Nam-Goong; Eun Sook Kim; Jin Ook Chung; Dong-Hyeok Cho; Chang Won Lee; Young Il Kim; Dong Jin Chung; Kyu Chang Won; In Joo Kim; Tae Sun Park; Duk Kyu Kim; Hosang Shon Journal: Diabetes Metab J Date: 2020-08-12 Impact factor: 5.376